Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

7050 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-03-31

Study Completion Date

2029-08-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is researching 2 different experimental drugs called REGN7508 and REGN9933. The study is focused on people who have Peripheral Artery Disease (PAD), which means that the blood vessels in their arms and legs have become too narrow. People with PAD have a higher risk of getting blood clots after procedures like Lower Extremity Revascularization (LER), a procedure to improve blood flow in the legs and feet.

The aim of this study is to see how well REGN7508 and REGN9933 prevent life-threatening blood clots in participants with PAD who have recently had LER. The effects of REGN7508 and REGN9933, individually, will also be compared to rivaroxaban and a placebo.

The study is looking at several other research questions, including:

* What side effects might happen from taking the study drugs and how do they compare to the side effects of rivaroxaban
* How much study drug is in the blood at different times
* Whether the body makes antibodies against the study drugs (which could make the drugs less effective or could lead to side effects)
* If the study drugs affect the ability of the blood to clot normally

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization

NCT03006770

Critical Limb Ischemia (CLI)

COMPLETED PHASE3

Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease.

NCT00798005

Severe Peripheral Artery Occlusive Disease

COMPLETED PHASE2

Efficacy and Safety of XRP0038/NV1FGF in Critical Limb Ischemia Patients With Skin Lesions

NCT00566657

Peripheral Vascular Diseases

COMPLETED PHASE3

The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease

NCT05009862

Peripheral Arterial Disease

ACTIVE_NOT_RECRUITING PHASE4

Safety and Tolerability of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease

NCT01157156

Peripheral Arterial Occlusive Disease

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Artery Disease (PAD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Cohort 1 of this study is double-blinded, and for Cohort 2 the participants, sponsor, and the investigators will be blinded to REGN7508 or REGN9933, but rivaroxaban will be administered as open-label.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

Group Type EXPERIMENTAL

REGN7508

Intervention Type DRUG

Administered per the protocol

REGN9933

Intervention Type DRUG

Administered per the protocol

Placebo

Intervention Type DRUG

Administered per the protocol

Cohort 2

Group Type EXPERIMENTAL

REGN7508

Intervention Type DRUG

Administered per the protocol

REGN9933

Intervention Type DRUG

Administered per the protocol

Rivaroxaban

Intervention Type DRUG

Administered per the protocol

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

REGN7508

Administered per the protocol

Intervention Type DRUG

REGN9933

Administered per the protocol

Intervention Type DRUG

Placebo

Administered per the protocol

Intervention Type DRUG

Rivaroxaban

Administered per the protocol

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Successful LER distal to the external iliac artery for ischemia due to atherosclerotic disease within 10 days prior to randomization as described in the protocol
2. At least 1 enrichment factor for major thrombotic vascular events:

1. Bypass with prosthetic graft
2. Endovascular treatment with stenting
3. Target lesion length \>15 cm
4. History of LER or amputation for PAD prior to qualifying LER
5. Type 2 diabetes mellitus requiring treatment
6. Comorbid symptomatic coronary artery disease as described in the protocol
7. Chronic kidney disease as described in the protocol
8. Age ≥75 years

Exclusion Criteria

1. Has any active clinical condition requiring therapeutic anticoagulation after the index revascularization including known triple positive antiphospholipid syndrome
2. Has known bleeding diathesis, platelet count \<50,000/mm\^3 or history of non-traumatic intracerebral hemorrhage, known cerebral amyloid angiopathy, or known unrepaired cerebrovascular malformations
3. Has recent coronary revascularization as described in the protocol
4. For Cohort 2 only: Has Glomerular Filtration Rate (GFR) \<15 mL/min/1.73m\^2 within 14 days prior to randomization or on dialysis or expected to be started on dialysis within the next 12 weeks starting from randomization
5. Has any other condition or therapy which would make the participant unsuitable for this study or not allow participation for the full planned study period
6. Has allergy, hypersensitivity, or other contraindication to REGN7508, REGN9933, or rivaroxaban (Cohort 2 only) or their excipients

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No